Table IV.
Details of the patient cohorts included in the investigation of the influence of aseptic lymphocyte-dominated vasculitis-associated lesion (ALVAL) on joint fluid metal ion concentrations
| ASR resurfacings | Mixed implant cohort | |
|---|---|---|
| Hips, n | 76 | 178 |
| Device type | ASR resurfacings | 36 mm MoM: 105 |
| ASR XL: 45 | ||
| BHR resurfacings: 26 | ||
| Durom resurfacings: 2 | ||
| Age (yrs)* | 54 (29 to 75) | 59 (22 to 84) |
| Male:female | 33:43 | 53:125 |
| Total volumetric wear rate (mm3 per yr)* | 7.10 (0.62 to 95.5) | 2.28 (0.23 to 69.1) |
| Duration in vivo (mths)* | 54 (8 to 108) | 61 (11 to 136) |
| Acetabular component size (mm)* | 54 (46 to 64) | 53 (44 to 64) |
| Joint fluid Cr (µg/l)* | 1622 (26 to 195 947) | 455 (13 to 133 120) |
| Joint fluid Co (µg/l)* | 855 (26 to51 487) | 605 (9 to 46 433) |
| ALVAL grade 3 (severe), % | 17 | 22 |
| Ratio of small:large fluid collection: | 20:56 | 49:129 |
*
median values
ASR, Articular Surface Replacement; MoM, metal-on-metal; BHR, Birmingham Hip Resurfacing; Cr, chromium; Co, cobalt